News

Pennsylvania to receive $1.2M from Gilead over kickback scheme to promote HIV drugs
Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...
Applied Clinical Trials Online35m
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...
Zacks Investment Research on MSN4h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...
WHO Endorses Injectable Lenacapavir As ‘Game-Changer’ In Global HIV Prevention Strategy
WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...
Bhekisisa6h
SA gets R520-million to buy the twice-a-year anti-HIV jab — but there’s a snag
SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...
Minnesota recovers $256,000 in Medicaid dollars as part of fraud settlement with HIV drugmaker
State attorneys general and federal prosecutors alleged Gilead Sciences illegally bankrolled lavish events for prescribers.
Explore more
Nevada secures nearly $500k in national settlement over fake HIV drug scheme
Nevada Attorney General Aaron Ford announced that the state will receive nearly $500,000 as part of a $202 million settlement ...
Hoodline18h
Gilead Sciences Inc. Agrees to $202 Million Settlement Over Kickbacks, Illinois Leads Charge with Multi-State Coalition
Gilead Sciences Inc. settled for $202 million over illegal kickbacks for HIV drug prescriptions, following Attorney General ...
Crain's New York Business21h
Gilead reaches $202M settlement over kickback scheme to promote HIV drug
Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...
J&J leads big pharma higher after earnings despite Trump’s latest tariff threat
After posting a double beat for Q2 2025, J&J (NYSE:JNJ), the pharma sector’s bellwether for the earnings season, added ~6% on Wednesday, marking its biggest intraday gain in nearly two years and ...